Central serous chorioretinopathy. Central serous chorioretinopathy
Conditions
Interventions
Intervention 1: Intervention group: Crocin one tablet 15 mg/day before breakfast for 2 months. Intervention 2: Control group: Placebo one tablet 15 mg/day before breakfast for 2 months.
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: age of 18-60 years old The diagnosis of CSCR based on clinical and imagining evaluation informed consent
Exclusion criteria
Exclusion criteria: Chronic Central SerousChorioretinopathy (CSCR) Laser treatment (6 months prior to enrollment) Intravitreal injection (3 months prior to enrollment) Other retinal diseases History of eye diseases Diabetes Mellitus Renal or hepatic diseases Allergy to saffron or crocin Pregnancy or lactation Beta-blocker, diuretic, or corticosteroid (1 week prior to enrollment) Bleeding tendency or any coagulation disorder
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best-corrected visual acuity (BCVA). Timepoint: 8 weeks. Method of measurement: Snellen chart.;Foveal thickness. Timepoint: 8 weeks. Method of measurement: Optical coherence tomography (OCT).;Subretinal fluid height. Timepoint: 8 weeks. Method of measurement: Optical coherence tomography (OCT).;Subfoveal choroidal thickness. Timepoint: 8 weeks. Method of measurement: Optical coherence tomography (OCT).;Need to Laser Therapy. Timepoint: 8 weeks. Method of measurement: clinical evaluation.;Safety and tolerability. Timepoint: 8 weeks. Method of measurement: based on patients reported adverse events. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMojtaba Heydari
Shiraz University of Medical Sciences
Outcome results
None listed